BE in a statement on Thursday said it will leverage its experience to develop and commercialise the vaccine candidate, which currently is produced using a proven yeast-based expression technology.
Terming the agreement with the Hyderabad headquartered vaccine maker a “timely” one, Dr Peter Hotez, professor and dean of the National School of Tropical Medicine at Baylor, and also co-director of Texas Children’s Centre for Vaccine Development, said, “This week’s information that India has become the third-leading nation in terms of COVID-19 cases has sparked concern that COVID-19 will become widespread and a serious and deadly infection across the crowded urban areas of South Asia.”
Claiming that their vaccine centre was advancing global health vaccines to prevent neglected and emerging diseases over the past two decades, Dr. Maria Elena Bottazzi, associate dean of the National School of Tropical Medicine at Baylor and co-director of Texas Children’s Center for Vaccine Development, said they “look forward to facilitating the technology transfer for the COVID-19 vaccine to India and for the world.”
“The partnership with Baylor would help accelerate the development of an affordable vaccine, especially for India and other low- and middle-income nations,” said Mahima Datla, Managing Director of BE. “BE is pleased to be a part of the global scientific effort aimed at exploring ways to respond to the COVID-19 pandemic.”
Narender Dev Mantena, BioE Holdings Inc’s director heading BE’s novel vaccine initiative said, the company would look forward to leveraging its capabilities for the development and manufacturing of the much needed vaccine. “If the vaccine development is successful, we expect to make several hundred million doses of the vaccine available annually.”